Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives
The DOI matches its Crossref record; 338 of the 350 references it cites were found in a registry or an index.
Abstract
Corticosteroids remain the mainstay of the treatment for various ocular conditions affecting the ocular surface, anterior and posterior segments of the eye due to their anti-inflammatory, anti-oedematous, and anti-neovascularization properties. Prednisolone, prednisolone acetate, dexamethasone, triamcinolone acetonide, fluocinolone acetonide, and loteprednol etabonate are amongst the most widely used ophthalmic corticosteroids. Corticosteroids differ in their activity and potency in the eye due to their inherent pharmacological and pharmaceutical differences. Different routes and regimens are available for ocular administration of corticosteroids. Conventional topical application to the eye is the route of choice when targeting diseases affecting the ocular surface and anterior segment, while periocular, intravitreal, and suprachoroidal injections can be potentially effective for posterior segment diseases. Corticosteroid-induced intraocular pressure elevation and cataract formation remain the most significant local risks following topical as well as systemic corticosteroid administration. Invasive drug administration via intracameral, subconjunctival, and intravitreal injection can enhance ocular bioavailability and minimize dose and dosing frequency of administration, yet may exacerbate ocular side effects of corticosteroids. This review provides a critical appraisal of the ophthalmic uses of corticosteroid, routes of administration, drug delivery fundamentals and novel ocu…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Briefly, gastroin testinal disturbance, osteoporosis, metabolic syndrome, cardiovascular disease, acne, sleep changes, cataracts, glaucoma, and the resulting polypharmacy (proton pump inhibitors, vitamin D, statins, antihyper tensives, etc.) can severely disrupt patient quality of life.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Gaballa et al., 2021
Citations
Cites
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149 · cited 3×
“Corticosteroids exert anti-inflammatory activities via genomic and nongenomic effects [61, 85].”
BackgroundGaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406
Adverse effects of topical glucocorticosteroids
Hengge, U. R., Ruzicka, T., Schwartz, R. A., & Cork, M. J. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.01.010 · Cited by 1,151
Diabetic Retinopathy: A Position Statement by the American Diabetes Association
Solomon, S. D., Chew, E., Duh, E. J., Sobrin, L., Sun, J. K., VanderBeek, B. L., Wykoff, C. C., & Gardner, T. W. (2017) · Diabetes Care · doi:10.2337/dc16-2641 · Cited by 940 · cited 1×
“following branched/central retinal vein occlusion, diabetic macular edema (DME) in patients post-cataract surgery [5, 6], DME in patients who have a history of intraocular pressure (IOP) elevation following corticosteroid dosing, diabetic retinopathy (DR) [7], age-related macular degeneration (AMD) [8], and postoperat…”
BackgroundInfluentialRacial Variations in the Prevalence of Primary Open-angle Glaucoma: The Baltimore Eye Survey
Tielsch, J. M. (1991) · JAMA · doi:10.1001/jama.1991.03470030069026 · Cited by 879
Side Effects of Corticosteroid Therapy
Buchman, A. L. (2001) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200110000-00006 · Cited by 745 · cited 1×
“In addition, it may lead to serious acute and chronic systemic side effects throughout the body including osteoporosis [137, 138], immunosuppression, Cushing’s syndrome [139, 140], adrenal suppression [141], and elevated blood pressure [135, 142].”
BackgroundRetinal nerve fiber layer analysis in the diagnosis of glaucoma
Zangwill, L. M., & Bowd, C. (2006) · Current Opinion in Ophthalmology · doi:10.1097/01.icu.0000193079.55240.18 · Cited by 595 · cited 10×
“For more discussion and examples on the elevation of IOP with age in response to corticosteroids, the reader is referred to the review published by Jones and Rhee [108].”
BackgroundMethodInfluentialGenomic and nongenomic effects of glucocorticoids
Stahn, C., & Buttgereit, F. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0898 · Cited by 594 · cited 1×
“The nongenomic mechanism exerts rapid effects on immune cells and regulate cell adhesion [86] and involves the inhibition of dilatation of the blood vessels, vascular permeability, and leukocyte migration [85, 87] through the inhibition of phospholipase A2.”
BackgroundPharmacokinetics and Pharmacodynamics of a Sustained-Release Dexamethasone Intravitreal Implant
Chang-Lin, J.-E., Attar, M., Acheampong, A. A., Robinson, M. R., Whitcup, S. M., Kuppermann, B. D., & Welty, D. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5285 · Cited by 590
Solubility and partitioning I: Solubility of nonelectrolytes in water
Yalkowsky, S. H., & Valvani, S. C. (1980) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600690814 · Cited by 577
Research works printed but not linked: 8
- Haller JA. Intravitreal corticosteroids: a review of therapeutic and surgical applications. Retina Today. 2009;S1:1–15.
- Moffat AC, et al. Clarke’s analysis of drugs and poisons. Vol. 3. London: Pharmaceutical press; 2011.
- Alberth M, et al. Lipophilicity, solubility and permeability of loteprednol etabonate: a novel, soft anti-inflammatory steroid. Aust J Biol Sci. 1991;2(2):115–25.
- YANG Y, et al. Intravitreal corticosteroids in diabetic macular edema. Retina. 2015;35:2440–9. · DOI
- Jones R, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17:163–7.
- Wilson M. Epidemiology of chronic open-angle glaucoma. Glaucomas. 1996;2:753–68.
- Patane MA, et al. Ocular iontophoresis for drug delivery. Retina Today. 2011;6:64–6.
- Patane M, et al. Randomized, double-masked study of four iontophoresis dose levels of EGP-437 in non-infectious anterior segment uveitis subjects. Invest Ophthalmol Vis Sci. 2010;51(13):5263.
Cited by
Nanotechnology-based ocular drug delivery systems: recent advances and future prospects
Li, S., Chen, L., & Fu, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01992-2 · Cited by 277
“Lipophilic and small-molecule drugs can pass through the BAB and exit the anterior compartment more rapidly than hydrophilic and large-molecule drugs.”
BackgroundInfluentialOcular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Kim, H. M., & Woo, S. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010108 · Cited by 198
“These microcrystal TA drug particles form a depot after intravitreal injection, thereby inducing controlled release and long-lasting therapeutic effects [71].”
BackgroundDexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems
Madamsetty, V. S., Mohammadinejad, R., Uzieliene, I., Nabavi, N., Dehshahri, A., García-Couce, J., Tavakol, S., Moghassemi, S., Dadashzadeh, A., Makvandi, P., et al. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00026 · Cited by 172
Considerations for Polymers Used in Ocular Drug Delivery
Allyn, M. M., Luo, R. H., Hellwarth, E. B., & Swindle-Reilly, K. E. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.787644 · Cited by 159
Abdelkader, H., Fathalla, Z. M. A., Seyfoddin, A., Farahani, M., Thrimawithana, T. R., Allahham, A., Alani, A. W. G., Al-Kinani, A. A., & Alany, R. G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113957 · Cited by 125
Self-citation
Metadata
- Authors
- Gaballa, S. A., Kompella, U. B., Elgarhy, O., Alqahtani, A. M., Pierscionek, B., Alany, R. G., & Abdelkader, H.
- Affiliations
- Minia University (EG)
- University of Colorado Anschutz (US)
- King Khalid University (SA)
- University of Staffordshire (GB)
- University of Auckland (NZ)
- Deraya University (EG)
- Corresponding author
- Abdelkader, Hamdy
- ORCID
- Venue
- Drug Delivery and Translational Research
- Published
- 2020-09-08
- Volume
- 11
- Issue
- 3
- Pages
- 866-893
- ISSN
- 2190-393X (ISSN-L)
- 2190-3948
- OpenAlex
- W3083822372
- Cited by
- 255
- References
- 350
- Citations by year
- 2026: 36 · 2025: 58 · 2024: 69 · 2023: 52 · 2022: 28 · 2021: 11 · 2020: 1
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Drug Delivery and Translational Research (publishedVersion)
- PubMed (publishedVersion)
- Research Repository (Kingston University London) (acceptedVersion)
- Staffordshire Online Repository (Staffordshire University) (acceptedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Keywords
- ocular drug delivery, prednisolone, dexamethasone, triamcinolone acetonide, fluocinolone acetonide, loteprednol etabonate, intravitreal injection, intracameral injection, suprachoroidal injection, periocular injection, topical ocular administration, intraocular pressure elevation, cataract formation, ocular surface disease, anterior segment diseases, posterior segment diseases, ocular implants, anti-inflammatory therapy, ocular adverse effects
- MeSH terms
- Adrenal Cortex Hormones, Eye Diseases, Glucocorticoids, Humans, Ophthalmology, Triamcinolone Acetonide, Drug Delivery Systems, Administration, Ophthalmic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. https://app.cochat.ai/papers/10.1007/s13346-020-00843-z
- The paper
- Gaballa, S. A., Kompella, U. B., Elgarhy, O., Alqahtani, A. M., Pierscionek, B., Alany, R. G., & Abdelkader, H. (2021). Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-020-00843-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.